Presentación
TRANSLATIONAL RESEARCH IN PEDIATRIC ONCOLOGY, HEMATOPOIETIC TRANSPLANTATION AND CELL THERAPY

cancerinfantil@idipaz.es

Excellent Group
Composition
Name
Position
Institution
Antonio Pérez Martínez
Facultativo Especialista de Área en Pediatría, Oncología y Hematología
Hospital Universitario La Paz
David Bueno Sánchez
Facultativo Especialista de Área en Pediatría, Oncología y Hematología
Hospital Universitario La Paz
Eva Couto Serrano
Asistente Ejecutiva
Hospital Universitario La Paz
Adela Escudero López
Investigadora Postdoctoral
Hospital Universitario La Paz
Cristina Ferreras Puente
Investigadora Postdoctoral
Hospital Universitario La Paz
Berta González Martínez
Facultativo Especialista de Área en Pediatría
Hospital Universitario La Paz
Pilar Guerra García
Facultativo Especialista de Área en Pediatría, Oncología y Hematología
Hospital Universitario La Paz
Alfonso Navarro Zapata
Investigador Predoctoral
Hospital Universitario La Paz
Pedro María Rubio Aparicio
Facultativo Especialista de Área en Pediatría, Oncología y Hematología
Hospital Universitario La Paz
Beatriz Ruz Caracuel
Investigadora Bioinformática
Hospital Universitario La Paz
Sonsoles San Román Pacheco
Facultativo Especialista de Área en Pediatría, Oncología y Hematología
Hospital Universitario La Paz
Strategic Objective
Our research program focuses on the molecular and immunological characterization of childhood cancer; the development of cell therapies, primarily through the susceptibility of tumor cells to Natural Killer cells; and the optimization of hematopoietic stem cells  transplantation.
Research Lines
• Analysis of solid / hematological tumors samples to determine their susceptibility to cell therapy, at functional, protein expression and genetic level.
• Cell therapy with activated NK cells in childhood cancer.
• Hematopoietic progenitor transplantation as a platform for cell therapy.
• Cell therapy with memory T lymphocytes as adoptive immunotherapy in transplantation of haematopoietic progenitors.
• Optimization of cell therapy by the generation of an NKG2D antigenic chimeric receptor (NKG2D-CAR). Evaluation of its specificity, persistence and activity (in vitro and in vivo) for the treatment of childhood cancer.
• Optimization of NK cell therapy using nanotechnology and antigenic chimeric receptors (CAR).
• Induction of immunological tolerance in solid organ transplantation through the induction of hematopoietic mixed chimerism by cell therapy
• Development of academic clinical trials and collaborations with the pharmaceutical industry as a strategy for the development of new therapies more effective and with fewer side effects in childhood cancer.